NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) has met the needed application requirements for approximately $1.0 million worth of grants from the National Institute of Health (NIH) in the development of its Listeria monocytogenes platform.
